Abbvie-Header Abbvie-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Filgotinib

            Therapeutic Area: Gastroenterology Product Name: GS-6034

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 23, 2021

            Details:

            This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study, This study showed the efficacy and tolerability of filgotinib 200 mg once daily, and no new safety risks were identified.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Filgotinib

            Therapeutic Area: Gastroenterology Product Name: Jyseleca

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 04, 2021

            Details:

            Of the 240 participants who were able to be evaluated after 13 weeks of treatment, sperm concentration fell by 50% or more in eight out of 120 in the filgotinib group and 10 out of 120 in the placebo group.